Posted by Michael Wonder on 24 Oct 2020
New cancer treatment with the precision drug Vitrakvi is included in the high-cost protection
23 October 2020 - For the first time in Sweden, a cancer drug against a specific genetic change, instead of against a certain form of cancer, is included in the high-cost protection.
The TLV has now decided that Vitrakvi (larotrectinib sulphate) should be included in the high-cost protection for patients who start their treatment before the age of 18.
